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Abstract
Herbal medicine (HM) is a type of medicine that uses active ingredients made from plants to treat diseases and
maintain health and wellbeing. Due to its increasing worldwide usage, the possibility of HMs and conventional drugs
being concurrently used is high, potentially leading to adverse events resulting from herb-drug interactions. Despite the
safety concerns regarding such interactions, few studies have been conducted for assessing clinical consequences of
using HMs with conventional drugs in real-world settings. As clinical trials are not forthcoming rapidly enough to
provide the evidence for herb-drug interactions, observational studies are considered as an alternative approach. The
present review focuses on evaluating the utility of analyzing real-world data in observational research to study the
clinical consequences of herb-drug interactions between HMs and conventional drugs. The data sources and study
designs of each highlighted literature are examined based on its strengths and limitations in analyzing herb-drug interactions. Finally, future observational studies involving novel and rigorous methodologies that may be effective in
studying herb-drug interactions are discussed.
Keywords: Herb-drug interactions, Herbal medicines, Observational studies, Real-world evidence

1. Introduction

H

erbal medicine (HM) is one of the oldest
methods used in treating health-related issues
and specializes in the utilization of medicinal plants.
Over the years, HM has been increasingly used by
countries worldwide for various health beneﬁts and
disease treatments. The World Health Organization
has stated that an estimated 80% of the world's
population is using herbal products for health care
reasons, particularly in developing countries where
HM is often considered as a primary source of
healthcare treatment [1]. In India and Africa,
70e90% of the country's population takes HMs,
respectively, while 40% of the healthcare in China
involves HMs [2]. With the rapid growth of HMs
usage, the concerns about the potential herb-drug
interactions remain when HMs are concomitantly
used with conventional drugs (i.e., standard medicines prescribed in the medical system). A systematic review has recently reported a substantial
concurrent use of HMs and conventional drugs

among older adults [3]. In addition, there is a
tremendous increase in the use of HMs over the last
few decades, estimating that around 20e35% of
patients prescribed on conventional drugs are also
taking herbal products [4]. Given these ﬁndings, it is
very likely that HMs are concurrently used with
conventional drugs among patients seeking treatments in general. Yet, despite its increasing popularity, many public health issues and safety concerns
of concomitant use of HMs and conventional drugs
are currently left unanswered.
To date, few studies have been conducted to
examine the prevalence of co-utilizing HMs and
conventional drugs, and even fewer studies were
performed to evaluate the safety and effectiveness of
herb-drug interactions. Typically, a randomized
controlled trial (RCT) is the gold standard method
used to determine the efﬁcacy of drugs; however, in
the case of HM, ethical considerations, fragmented
health care system, and the highly individualized
dosing regimen of herbs make the situation difﬁcult
for researchers to conduct RCTs when investigating
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the clinical consequences of herb-drug interactions
[5]. In addition, HMs can be used at different dosages depending on the symptoms of disease, making it difﬁcult for RCTs to comprehensively reﬂect
HMs usage in real-world settings [6]. Furthermore,
as RCTs are usually conducted in a controlled
setting with selected patients, certain proportion of
patients in a population may be under-represented,
thus affecting its generalizability due to their
rigorous inclusion and exclusion criteria. As clinical
trials are not advancing fast enough to meet the
public's need for knowledge on the effectiveness
and safety of herb-drug interaction, alternative
research methods should be considered.
Currently, the main alternative approach to conducting herb-drug related studies involves the
utilization of observational studies to gather realworld evidence, which comprises the information
generated from real-world data via multiple
possible sources such as administrative claims
database, hospital records, and surveys [7]. Despite
certain limitations, real-world studies allow researchers to examine the effects of herb-drug
combinations outside of controlled settings, even at
a population level [7]. Accordingly, real-world evidence from observational studies is essential in
bridging this gap to provide the swift information
on the utilization, effectiveness, and safety of HMs
and to study the clinical consequences from any
interactions with conventional drugs. Owing to the
lack of a comprehensive review concentrating on
real-world evidence of beneﬁcial or harmful effects
from the combined use of HMs and conventional
drugs in prior literature, this review article aimed
to evaluate the utility of analyzing real-world data
in observational research studying the clinical
consequences of concomitant use of HMs and
conventional drugs, primarily through the elucidation of the adopted data sources and study designs and the discussion on future research
directions.

2. Real-world data sources
At present, observational studies have been performed to utilize real-world data for assessing potential herb-drug interactions. In this review paper,
we discussed the strengths and limitations of utilizing real-world data via observational methodologies to study the potential herb-drug interactions
between HMs and conventional drugs. In addition,
we evaluated whether real-world evidence generated by observational studies is a useful tool in
studying this ﬁeld of interest by discussing the
currently adopted methods and the state-of-the-art
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pharmacoepidemiologic approaches that can be
utilized in the future.
2.1. Health insurance claims database
The ﬁrst approach to conducting real-world study
on the herb-drug interactions is the one that uses
health insurance claims database as the data source.
Health insurance claims database is a largescale
electronic record that provides demographic information and clinical data and is often used in
observational studies to obtain real-world evidence.
For instance, the Taiwanese National Health Insurance Research Database (NHIRD) is one of the
largest health insurance claims database around the
world and it covers comprehensive information on
encrypted demographics (date of birth and age),
disease diagnoses, procedures and prescribed
medications (including conventional drugs and
Chinese HMs) from outpatient, inpatient and
emergency care. In the NHIRD, detailed drug records contain drug names, prescription dates, prescription reﬁll dates, total doses, days of supply, and
frequency of drug usage [8]. Despite abundant drug
information contained in health insurance claims
databases, these data cannot directly reveal whether
there are any clinical consequences from exposure
to herb-drug interactions because there is no column in the database to indicate this kind of information. Therefore, to assess whether exposure to
herb-drug interactions could cause a beneﬁcial or
harmful effect in the real-world, a health insurance
claims database needs to be assessed, analyzed, and
coupled with an appropriate observational study
design and statistical approach.
Although health insurance claims database is
commonly used as a data source for clinical researches [8], there are only a few studies that have
utilized this approach to examine the clinical consequences of herb-drug interactions. To date, the
majority of studies that used health insurance
claims database focused on the effects and safety of
HM alone while only a handful of studies explored
potential herb-drug interactions (i.e., without
examining the hard end points associated with the
aforementioned interactions) among patients with
various diseases.
Of the very few studies that utilized health insurance claims database to examine the clinical
consequences associated with the exposure to the
combined use of HMs and conventional drugs, the
cohort study by Hsu et al. analyzed a nationwide
health claims database and revealed a decreased
risk of endometrial cancer associated with the use of
Chinese herbal product Ginseng among breast
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cancer (BC) survivors treated with tamoxifen [9].
The study became the ﬁrst of its kind to report such
an association and found the possible beneﬁcial
interactive effects between Ginseng and tamoxifen in
regard to endometrial cancer development among
BC survivors. Another cohort study by Wu et al. also
found the inhibition of the subsequent endometrial
cancer among the same tamoxifen-treated BC population concomitantly receiving the herb Dang-qui
[10]. This study suggested that the association
observed may be due to a mechanism that involves
the inhibition of MGMT protein expression, resulting in a synergistic antiproliferative effect upon the
combined use of Dang-qui and tamoxifen use. While
further research is deﬁnitely needed to conﬁrm the
ﬁndings from the study by Hsu et al. and Wu et al.,
both studies serve as the stepping-stones in understanding the effectiveness of using tamoxifen with
Ginseng and Dang-qui, respectively. Their ﬁndings
also pointed out that the clinical consequences from
herb-drug interactions could be beneﬁcial. On the
other hand, a cross-sectional study with analysis of
the Taiwan National Health Insurance Research
Database (NHIRD) reported no increased risk of
hemorrhage with the concurrent use of the herbal
medicine Gingko biloba extract (GBE ) and antiplatelet/anticoagulant agents, but found the univariate
estimate of relative risk for hemorrhage in older
patients (65 years old) to be signiﬁcant [11].
Based on the three studies discussed, there are
several strengths that are worth mentioning with
regards to using health insurance claims database
as the data source for conducting herb-drug related
researches. All the studies were able to obtain the
information from a nationwide health insurance
claims database, allowing not only a relatively large
sample size but also increasing the overall generalizability of the ﬁndings due to its nationwide
scale. In addition, due to the nature of using claims
database, minimum recall bias and higher
congruence with patients’ medical records
compared to that with data obtained from questionnaires may be expected. The three studies also
all happen to be conducted in Taiwan, even though
these studies were not intentionally selected, suggesting that the possibility of using health insurance claims database to study potential herb-drug
interactions is currently a challenge in other
countries due to the lack of coverage of HM in their
respective health insurance programs. In Taiwan,
on the other hand, the coexistence of conventional
drugs and HMs, particularly Chinese herbs, is a
notable feature in the health care system, an aspect
that may have stemmed from its long history in
developing and utilizing HMs. The NHIRD utilized

by the three studies provides not only prescriptionreﬁll data and dosage records of conventional
drugs but also the information on HM formulae
and single herbs, allowing population-based
studies to be performed.
Using health insurance claims database, however,
also comes with certain limitations [8]. As
acknowledged by all the studies, the database does
not include over-the-counter prescriptions of conventional drugs or HMs, nor does it factor in the
possibility of herbs being consumed in health foods.
As a result, the co-prescription of HM and conventional drug may be underestimated. In addition, all
three studies had incomplete comparability in terms
of the baseline characteristics between comparison
groups, in which only the bare minimum characteristics were presented. It is also unclear whether
baseline characteristics were balanced during subgroup analyses. Furthermore, there seems to be no
statistical adjustments made for imbalanced
comorbidities and co-medications in each respective
study, raising the concern for potential confounding.
Lastly, even though the Taiwanese national health
insurance claims database includes records of HMs,
it is still limited to herbal products that are reimbursed in the health care system, meaning that
certain HMs may still be unavailable for being
evaluated as real-world data. Thus, the approach of
using claims database to study potential herb-drug
interactions may be currently limited to certain HMs
and countries only.
2.2. Electronic health records
The second approach to studying herb-drug
interaction in real-world settings involves utilizing
electronic health records (EHR) as the data source.
EHR is a longitudinal collection of electronic records
of a patient's medical information as well as
administrative encounters between the patient and
their health-care provider [12]. It is essentially an
electronic copy of a patient's medical chart that includes their past medical history, treatment plans,
diagnoses, and laboratory results. While the EHR
system is considered as a common and useful tool in
the health-care settings, it is not commonly used as
the sole data source in herb-drug related studies.
Among the few studies that only utilized EHR as
their data source, the prospective cohort study by
Lopatin et al. was conducted at 16 clinical centers to
evaluate the following three treatment options for
chronic rhinosinusitis (CRS): oral antibiotics plus
the herb Cyclamen europaeum (CE ), CE in monotherapy, and oral antibiotics alone [13]. By analyzing
multicenter EHRs, this study was able to show that

CE in monotherapy or in combination with a standard oral antibiotic signiﬁcantly reduced CRS
symptoms and recurrences compared to oral antibiotics alone among patients with CRS exacerbation.
Thronicke et al. also conducted an observational
cohort study using EHR to analyze the rate of
adverse events (AE) among cancer patients who
took immune checkpoint inhibitors (ICM) with and
without the herbal medicine Viscum album L. (VA);
however, no signiﬁcant differences in the AE rates
were found between the two groups [14]. Despite
the comparable results of AE rates across both
groups, this study was the ﬁrst to give an insight on
the application of herbal medicine VA in patients
with metastatic or advanced cancer and it provided
a ﬁrst impression on the safety aspects of using VA
and ICM concomitantly.
The strengths of utilizing EHR as the data source
are similar to those of claims database. However,
one main difference between the two data sources is
the additional laboratory records that EHR provides.
As EHR can obtain large datasets that include
extensive laboratory data and hospital test results, it
provides an additional layer of information about
the patients that could potentially be impactful to
the study outcome. Loptain et al. demonstrated this
by incorporating the nasal endoscopy test to objectively assess the study outcome in their herbal-drug
research, thus reducing the possibility of outcome
misclassiﬁcation [13]. Coupled with the fact that
EHR can also provide records on HMs that are not
exclusively limited to reimbursed herbs, this data
source provides a relatively complete dataset for
analysis.
Based on the studies mentioned, EHRs also
possess several limitations. The most notable one
reported in the studies is the potential confounding
by indication bias: as both studies determined the
allocation of patients to treatment groups at the
discretion of the physicians, it is likely that physicians may reserve the combined treatment of herbal
and conventional drug for patients who have
symptoms with greater severity. Additionally, the
possibility of patients seeking treatment in other
health-care facilities cannot be ruled out, which may
be a potential issue as not all electronic records are
linked. This is due to the fact that there are multiple
EHR systems across hospitals, sometimes even
hundreds depending on the country, across a population, each with their own customizations and
interfaces that make it difﬁcult for medical records
to be integrated. Furthermore, while EHR can
indeed provide data on non-reimbursed HM, this
data source still cannot encompass all the herbs that
a patient may have taken.
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2.3. Questionnaire
Another approach that is commonly used in realworld studies for evaluating potential herb-drug
interactions is the utilization of questionnaires.
Questionnaire is a type of research tool that can be
used to collect a variety of information from the
respondents depending on how it is designed.
When designing a questionnaire, questions raised
need to be reliable and valid [15]. The reliability and
validity of a survey refer to consistent measures
across different questions in a domain and high
degree of respondents’ answers to questions mapping on to what a study intends to measure,
respectively [15]. Accordingly, multiple scenarios
need to be avoided when designing questionnaires,
such as inadequate wording, poorly deﬁned terms,
and confusing questions as well as leading the patients to answer in a speciﬁc way [15]. Given its
relatively ﬂexible and cost-efﬁcient nature, questionnaire is one of the most frequently used approaches adopted in the studies assessing potential
herb-drug interactions. The aforementioned
reviewed studies utilizing questionnaires all assess
potential herb-drug interactions rather than the
actual interactions probably because outcomes are
difﬁcult to be determined from surveys. Additionally, observational studies using questionnaires
determined potential herb-drug interactions with
references to multiple sources of information, such
as databases, websites, and literature with documented or theoretical potential interactions between
HMs and conventional drugs.
Among many studies that used questionnaires as
the data source for their research, Jermini et al.
conducted a cross-sectional study on the concurrent
use of cancer treatment with complementary and
alternative medicine (CAM), a wide range of medical treatments that include the use of HM, to evaluate any potential interactions [16]. While the study
reported the prevalence of CAM use to be 45% in
patients receiving cancer treatments, no associations
were found to be clinically concerning in terms of
pharmacokinetic interaction potential. The researchers attributed this lack of association to the
fact that the questionnaire was conducted in only a
single hospital, resulting in the low rate of HM use
in their sample size. Contrastingly, Loquai et al.
conducted their cross-sectional study in 7 skincancer centers and reported potential herb-drug
interactions in 23.9% of patients concomitantly
receiving cancer treatment and CAM [17]. This
study was the ﬁrst in its ﬁeld that utilized the
questionnaire-based approach to study potential
interactions between CAM and antineoplastic
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treatment among melanoma-diagnosed patients.
Moreover, Djuv et al. conducted an herb-drug
interaction study from a different angle by focusing
on patients who had consultations with general
practitioners [18]. By utilizing the questionnaire
methodology, the study reported 255 herb-drug
combinations among the study population, 18 of
which were found to be at risk of clinically relevant
interactions, including antihypertensive and
diuretic drugs with Ginseng. As only a handful of
research has examined the concurrent use of HMs
and conventional drugs in primary care settings,
this is one of the few studies that evaluated patients
in general practice on the co-use of herb-drug
combinations and their potential interactions.
McLay et al., on the other hand, performed a crosssectional survey on pregnant women and found that
12.7% of the study population was exposed to herbdrug interactions with the potential to increase the
risk of various adverse events, including postpartum
hemorrhage, maternal and fetal central nervous
system depression, and alteration of maternal hemodynamics [19].
Considering all the studies mentioned, a number
of strengths merit the discussion pertaining to the
use of questionnaires as a data collection tool for
herb-drug related research. Due to the nature of this
observational method, questionnaires usually
require less time compared to other data sources
and are relatively cost-efﬁcient to perform. As researchers can decide the structure and format of the
questionnaire, this approach provides not only data
collection on HM and conventional drug use, but
also the information on any lifestyle drugs that may
not have been captured in the health insurance
claims database or EHR. An example of this is the
study by McLay et al., in which 40% of pregnant
women in the UK were reported to self-administer
HMs and natural products as additional nutrients
for their fetuses despite being on prescribed drugs
[19]. In addition, questionnaires also give further
insights on the current situation of herb-drug use in
health care settings; Djuv et al. demonstrated this in
their study, reporting that 80% of patients who coused HMs and conventional drugs did not inform
their physicians and doctors about their herbal use
[18]. With the majority of the respondents stating
that they simply were not asked about HM consumption, this implies a strong indication for health
care professionals to take the initiative to inquire
and identify potential herb-drug interactions.
Despite the ﬂexibility and wide coverage of information that questionnaires can provide, this data
source also has several limitations. One of the
biggest factors that can affect the data collected from

questionnaires is how the questions are designed.
Depending on whether the questions are closeended, open-ended, or a mixture of both, bias and
skewed feedbacks may occur. Based on the studies
discussed, Djuv et al. and McLay et al. both provided a list of herbal products, 24 and 40, respectively, in their questionnaire that they considered to
be commonly used. This may be a concern as it can
restrict the patients’ answers and lead them into
certain directions depending on the content of the
list [18,19]. Additionally, none of the mentioned
studies were able to validate the data they obtained
from the questionnaires since no EHR or health
insurance claims database were utilized. Furthermore, there is currently not a designated database
or “gold standard” database that serves as the main
source for providing comprehensive information on
the references to potential herb-drug interactions. In
other words, studies conducted via questionnaires
have to rely on various sources of information to
evaluate the potential interactions they have identiﬁed. This cross referencing among multiple databases to determine clinically relevant herb-drug
interactions may lead to heterogeneity across
different studies. Accordingly, although employment of questionnaires may be a convenient and
accessible tool to study potential herb-drug interactions, such method is still limited in its generalizability and function due to the nature of its
design.
2.4. Survey and electronic health records
The last commonly used approach to examining
herb-drug interactions is one that combines the
observational methodology of survey and EHR
together. While utilizing questionnaire alone is
effective in collecting multiple insights simultaneously, including information on potential herbdrug interactions and confounding variables, it is
still limited by its lack of validity. As such, many
studies have combined the utilization of survey and
questionnaire with EHR as a hybrid approach in
studying the interactions between HMs and conventional drugs. In this hybrid approach, both survey and EHR would be used as data sources to
collect information on herb-drug use from the
population of interest, providing a further examination on the current medicines consumed by
patients.
Of the numerous studies that used survey and
EHR to investigate herb-drug interactions [20e23],
Chi et al. found that among the elders aged 60 and
above, 43.3% of the participants who had concurrent
use of HMs and conventional drugs were exposed to

potential herb-drug interactions, with half of the
interactions related to HM with anticoagulant
properties [24]. Chi et al. analyzed the EHR to
measure important relevant data, including demographic characteristics and physician-diagnosed
history of chronic diseases, and adopted the survey
method to identify all medication use, including
HM, to which they later conﬁrmed in medical records. By utilizing both observational methodologies, this cross-sectional study was able to ﬁnd the
most common HMs and conventional drugs
involved in the identiﬁed interactions, including
herbs of Ginkgo and Ginseng, and conventional
drugs of antithrombotic agents and calcium channel
blockers. Their data provided the awareness and
emphasis on the common herb-drug combinations.
Levy et al. also conducted a cross-sectional study
using the survey and EHR hybrid approach and
found that 16.5% of the herb-drug users hospitalized in surgical departments had severe or moderate potential interactions with anesthetic drugs [25].
Furthermore, 19% of the herb-drug users also had
the potential to develop perioperative hemorrhage
due to herbal interactions with antithrombotic
drugs. Even with its limited sample size, this study
is one of the few studies that systematically analyzed
the potential herb-drug interactions in a perioperative setting. On the other hand, Drozdoff et al.
utilized the survey and EHR hybrid approach and
observed high overall use of HMs and conventional
drugs among patients undergoing chemotherapy
for breast and gynecological cancer, reporting 18.1%
of herb-drug users to have potential interactions
between HMs and metabolized anticancer drugs,
despite very few of the interactions considered to be
clinically relevant [26]. Al-Ramahi et al. also reported few potential herb-drug interactions to be
clinically relevant with employment of the combined survey and HER approach [27]. While the two
abovementioned studies did not ﬁnd many clinically
relevant interactions, their ﬁndings may still be used
as a starting point in that speciﬁc ﬁeld of interest.
Additionally, another two studies using surveys
with EHRs assessed the safety of herb-drug interactions. Levy et al. found that approximately half
of the patients took HMs during hospitalizations. Of
them, 47% had at least one potential herb-drug
interaction, which might inﬂuence drug metabolism
and cause serious adverse effects, such as bleeding
or hypotension [28]. Another study conducted by
Leung et al. reported a high prevalence of HMs use
in patients receiving warfarin, but revealed no association between the exposure to HMs and an
increased risk of self-reported bleeding events. It is
worth noticing that even though the standardized
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and ﬁxed questions used in the structure survey
used in Leung et al.'s study might increase reliability, it could avoid participants to respond in
much detail. In addition, the duration of HM usage
was vaguely deﬁned [29]. To sum up, although the
combined use of survey and EHR allows more
comprehensive information on herb-drug use, it
should be cautious about the potential methodology
ﬂaws, such as limited sample size and recall bias.
Future studies with bigger diverse populations and
further utilization of EHR in this hybrid approach is
needed, such as assessing hard-end outcomes from
EHR. Overall, current literature adopting the survey
and EHR combination approach primarily employs
questionnaires to obtain the information on the
combined use of HMs and conventional drugs and
accesses EHR to validate patients' reported data or
to obtain clinical hard-end outcomes.
The strengths of conducting studies via the survey
and EHR approach are similar to those that utilize
the two data sources alone. As mentioned previously, surveys have the advantages of collecting the
information on multiple herb-drug combinations at
once while EHR can provide higher accuracy of
medication usage than surveys. Based on the studies
discussed, the addition of utilizing EHR on top of
surveys allows researchers not only to conﬁrm the
use of HMs and conventional drugs that were disclosed in the surveys but also to examine patients’
medical history that may be used to assess hard-end
outcomes and confounders. As EHR provides records that are physician-diagnosed rather than selfreported, the accuracy of the information on herbdrug use is moved up to another level compared to
the studies that utilize either surveys or questionnaires alone. Additionally, this hybrid approach of
survey and EHR has the potential to look at actual
interactions between HMs and conventional drugs
rather than just theoretical assessment; however,
few studies have attempted this thus far, suggesting
a possible direction for future studies.
Conducting real-world studies via survey and
EHR also possesses certain limitations. While EHR
does provide an extra level of accuracy in data
collection, not all HMs are always conﬁrmed or
collected in medical records as they can be taken as
self-medication, or patients are simply not asked
about history of herbal usage. Therefore, the potential herb-drug interactions detected in observational studies that utilize this hybrid approach may
still be underestimated. In addition, although EHR
can provide data on comorbidities and comedications of patients, previous studies did not seem
to fully utilize this data source to adjust for patients’
comorbidities and comedications while assessing
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- Able to conﬁrm medical records reported from surveys via EHR
- Higher accuracy of data due to physician diagnosed records
- Potential to assess hard-end outcomes with EHR
Survey and EHR

- Issues of reliability and validity of items generated in questionnaires
- Lack of validation for answers obtained from questionnaire
- Requires online database to evaluate potential herb-drug
interactions, possible heterogeneity
- Possible underestimation of potential herb-drug interactions
- Requires online database to evaluate potential herb-drug
interactions, possible heterogeneity

Health Insurance
Claims Database

- Exclusion of over-the-counter records, possible underestimation
- EHRs not always integrated among different hospitals

Limitations
Strengths

Questionnaire

Electronic Health
Records (EHR)

Four common data sources were previously discussed in regard to their strengths and limitations
when used as real-world data to study the interactions between HMs and conventional drugs.
However, among the examined studies, only two
types of study designs were implemented: the more
frequently used cross-sectional design and the less
commonly adopted cohort design. Similar to the
data sources, different study designs also possess
their own advantages and shortcomings that may
affect the ﬁndings of the research (Table 2). The
following aimed to explore and discuss the main
strengths and drawbacks of these study designs to
obtain the real-world evidence of the interactions
between HMs and conventional drugs.
In terms of the most frequently used study designs in the aforementioned and discussed literatures, a cross-sectional study design is the most
dominant approach observed in the hybrid and
questionnaire only studies. Its frequent usage in this
ﬁeld of interest may be attributed to certain
strengths. First, a cross-sectional design is often
regarded as a relatively quick and easy method to
perform than most of the study designs as it requires little or even no waiting time for the outcome
to occur [30]. As a result, it provides rapid results of
descriptive information such as the prevalence of
herb-drug interactions and their distribution patterns in real-world settings. In addition, a cross-

Data Source

3. Study designs
Table 1. Summary of strengths and limitations of the common data sources used in observational studies.

REVIEW ARTICLE

herb-drug combinations. Instead, the majority of
studies that used survey and EHR for real-world
data mainly focused on the prevalence of theoretical
and potential interactions between HMs and conventional drugs. Furthermore, similar to the studies
that solely used either surveys or questionnaires as
their only data source, research that implemented
the hybrid approach still requires the use of various
sources of online database (i.e., cross referencing) to
evaluate potential herb-drug interactions. This remains an issue as utilizing multiple databases for
referencing potential herb-drug interactions creates
inconsistency that may cause different studies to
reach different conclusions about the same herbdrug combination. Despite these limitations, the
concurrent use of survey and EHR is arguably one
of the most common approaches observed in
studies regarding herb-drug interactions, possibly
due to its richness of available data compared to
other data sources, such as health insurance claims
database. A summary illustrating the differences in
the strengths and limitations of each data source can
be found in Table 1.

- Exclusion of over-the-counter records, possible underestimation
- Limited to records of herbal medicines that are reimbursed
- No laboratory data available

JOURNAL OF FOOD AND DRUG ANALYSIS 2022;30:316e330

Good generalizability
Minimum recall bias
Provides herbal medicine formulae and records (country-based)
Provide data on comorbidities and co-medications of patients
Laboratory data available
Herbal medicine records not limited to reimbursed ones
Provide data on comorbidities and co-medications of patients
Relatively quick and cost-efﬁcient
Provides information aside from medical records (lifestyle)
Collect data on multiple exposure combinations at once
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Can assess multiple exposures
Appropriate for rare outcomes
Appropriate for latent outcomes
Easy to perform
Likely to report a new association of interest for the ﬁrst time
Provide information for generating hypotheses
Case reports/case series

Case-control

Cohort

Note. Only cross-sectional and cohort studies were employed for the reviewed studies utilizing real-world data.
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sectional study design allows researchers to assess
the associations of multiple interactions simultaneously and to generate research hypothesis that
may be tested for future in-depth studies [30]. As
studies regarding actual interactions between HMs
and conventional drugs are currently still limited,
research carried out using this study design may
shed light on herb-drug interactions that are especially common and important to look further into.
Cross-sectional designs, however, also retain
some limitations. As cross-sectional studies measure both exposure and outcome either at a single
point in time or over a short time period, the temporality of the association between exposure and
outcome occurrence is uncertain [31]. Accordingly,
while it is possible to evaluate associations of herbdrug combinations with potential confounders,
studies using this design method cannot determine
whether the exposure of HMs with conventional
drugs precedes the outcome of interest, making it
difﬁcult to prove causality. Additionally, crosssectional studies are not ideal for studying rare
outcomes due to the difﬁculty of observing a sufﬁcient number of outcome events and the potential of
survival bias [31]. Nevertheless, cross-sectional
studies are still useful in the sense that they can
provide valuable descriptive feedbacks to inform
health care services on the planning of their resources and serve as the ﬁrst step of a research topic
or a pilot study for future prospective studies.
Cohort study design, on the other hand, is only
adopted in studies that utilized either the health
insurance claims database or EHR as a data source,
albeit very few. Despite its less frequent usage in
assessing herb-drug interactions, cohort design has
several strengths that are worth mentioning.
Perhaps one of the biggest advantages in adopting a
cohort study design is its clarity of temporal
sequence [32]. In other words, it allows researchers
to calculate the incidence rate of the outcome of
interest as the exposed and unexposed groups are
identiﬁed and subjects with the outcome of interest
are excluded at the beginning. Both groups are then
followed over time for various outcomes, which establishes the time sequence of events. Cohort design
could be especially useful when trying to demonstrate an association between the exposure to the
combined use of HMs and conventional drugs and
the risk of subsequent clinical consequences since
the temporality between the exposure and outcome
is well deﬁned [32]. Furthermore, cohort studies
have the ability to study multiple effects of a single
exposure, allowing studies to look at several adverse
and/or beneﬁcial effects of a speciﬁc herb-drug
combination at once [33].
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Not appropriate for assessing rare outcomes
Differential losses to follow-up can result in bias
May have limited/incomplete data in retrospective studies
Can be time-consuming in prospective studies
Issue of long latency period
Prone to confounding by indication bias and immortal time bias
Prone to selection bias
Unable to observe incident outcomes
Weak temporal relationship
Lack of control groups
Cannot establish a causal relationship
Limited generalizability
-

- Cannot establish causal relationships due to temporality of association
- Not ideal for studying rare outcomes or rare exposure
- Prone to survivor bias

Relatively quick and easy to perform, provides rapid descriptive results
Allows assessment of multiple interactions simultaneously
Give insights on prevalence of herb-drug interactions
Can generate hypothesis for future studies
Clarity of temporal sequence, can establish causal relationships
Allows calculation of incidence rate of outcomes
Can assess multiple effects of a single exposure
Cross-sectional

Limitations
Strengths
Study Design

Table 2. Summary of strengths and limitations of the common study designs used in the observational studies for evaluating herb-drug interactions.
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The limitations of utilizing a cohort study design
also warrant some discussion. While cohort studies
have the advantage of examining the temporal
relationship between an exposure and an outcome,
the differential losses of follow-up can introduce
bias to the study [31]. The existing data used in
retrospective cohort studies is also limited in its
quality and completeness because exposure and
outcome data as well as patients’ characteristics may
have already been recorded. This can result in an
underestimation of the herb-drug combination of
interest or lead to the misclassiﬁcation in the measurement of combined use of HMs and convention
drugs or clinical events of interest. For studying rare
outcomes, in order to allow enough outcomes to
occur, prospective cohort studies can be very timeconsuming because the study subjects are required
to be followed for a long period of time, and retrospective cohort studies need to be conducted via a
data source with long-term data, making a cohort
study design inefﬁcient in assessing this type of
outcome [30]. Moreover, when conducting a cohort
study, there is also the possibility and concern of
long latency period for certain herb-drug interactions, making it difﬁcult for researchers to
delineate a causal relationship between exposure to
herb-drug interactions and the outcome of interest.
Lastly, cohort studies in general are prone to confounding by indication bias and immortal time bias,
which should be addressed in the early phase of
designing cohort studies [34].

report studies. Taken together, despite the useful
clinical evidence of clinical consequences from the
previous reviews, the majority of the provided data
came from case reports and all reported safety
outcomes. Prior reviews focused on safety of herbdrug interactions probably because safety is the
primary focus in case reports. These characteristics
of the previous review reports, therefore, may pose
a threat to the external validity of the provided evidence of the examined herb-drug interactions.
Unlike the prior literature, our review included
observational studies with different analytical study
designs, such as cohort and cross-sectional studies.
Additionally, this current review focused on how
each of the employed study design and real-world
data source can contribute to the herb-drug
research and examined studies reporting beneﬁcial
and harmful effects. Accordingly, through documenting different types of analytical study designs
and data sources, this review provided valuable
clinical evidence complemented to the current data
of clinical consequences of the combined use of
HMs and conventional drugs. A summary illustrating the detailed information of each cited studies
in this review, including the corresponding data
source, type of study design, herbal medicine and
conventional drug being used, potential interactions/main ﬁndings, and lastly with potential
methodological ﬂaws can be found in Table 3.

4. Comparisons of the ﬁndings from current
review with prior literature

Although current studies have already utilized
real-world data to examine herb-drug interactions,
there are further areas in which this research
application can be improved. A case-control design,
a commonly used approach in observational
studies, is found not to be employed in herb-drug
interaction studies utilizing real-world data in this
review [37]. The inherent study limitations and the
nature of case-control studies, detailed in Table 2,
may signiﬁcantly limit their utility in drug-herb assessments; however, this kind of design is suitable
for investigating rare outcomes, latent outcomes,
and multiple exposures [38]. Therefore, when
appropriate, case-control studies can still be
considered in the future for providing real-world
evidence of herb-drug combinations.
As observational studies are prone to confounding and bias, novel approaches such as propensityscore (PS) matching and high-dimensional PS
analysis can be considered in future studies to
overcome the inherent limitations of real-world
studies, such as measured and unmeasured confounding [39,40]. Additionally, novel study designs

Previous literature that reviewed clinical data of
herb-drug interactions was dominated by case reports [35,36], which were distinctly different from
the examined observational studies in this review.
Izzo conducted an overview of herb-drug interaction reports and observed that the majority of the
assessed interactions had a negligible clinical signiﬁcance, while concomitant use of St. John's wort
with certain types of antiretroviral, anticancer,
immunosuppressive agents may cause serious
adverse events [35]. Notably, the overwhelming
majority of the data provided by Izzo were case reports; therefore, it is difﬁcult to infer a causal relationship from these case studies. Another review on
this herb-drug interaction topic documented 15
cases of adverse drug reactions among the examined 51 studies, among which 49 were case reports
[36]. The dominant case reports in the review by
Awortwe et al. [36] also limited the utility of the
provided information due to the nature of case-

5. Future directions for real-world studies

Table 3. Evaluation of observational studies assessing herb-drug interactions.
Data source

Study design

Herbal medicine

Conventional drug

Potential interactions/
Main ﬁndings

Potential methodological ﬂaws

Hsu et al. [9]

Health insurance
claims database

Cohort

Ginseng

Tamoxifen

- Uncontrolled disease
severity
- Not speciﬁed continuous use of herbal
medicine

Wu et al. [10]

Health insurance
claims database

Cohort

Dang-qui

Tamoxifen

Chan et al. [11]

Health insurance
claims database

Cross-sectional

Ginkgo biloba extract
(GBE)

Antiplatelet or anticoagulant agents

Lopatin et al. [13]

Electronic health
records

Cohort

Cyclamen europaeum
(CE)

Respiratory antibiotics
(amoxicillin, clarithromycin, etc.)

Thronicke et al. [14]

Electronic health
records

Cohort

Viscum album L. (VA,
mistletoe) extracts

Immune checkpoint
inhibitors (ICM)

Jermini et al. [16]

Questionnaire

Cross-sectional

Herbal medicines (Viscum album, Camellia
sinensis, etc.)

Anticancer treatments
(chemotherapy, radiotherapy, etc.)

A signiﬁcant inhibitory
relationship between
Ginseng consumption
and subsequent endometrial cancer among
breast cancer survivors
was found.
Dang-qui consumption
is common among
breast cancer survivors
and seems to decrease
the risk of subsequent
endometrial cancer.
Concurrent use of GBE
and antiplatelet/anticoagulant agents may
increase the risk of
bleeding in patients
with known bleeding
risks and in elderly.
Both CE in monotherapy or added to
antibiotics reduced
nasal symptoms and
chronic rhinosinusitis
recurrences compared
to antibiotics in
monotherapy.
Concomitant use of VA
may not alter ICMinduced adverse event
rates.
The prevalence of
Herbal medicines use
during cancer treatment was high (45%).
However, only a small
percentage of patients
had described the use
of herbal drugs to their
oncologists.

- Uncontrolled disease
severity
- Not speciﬁed continuous use of herbal
medicine
- Uncontrolled dose or
duration of herb
usage
- Random error

- Confounding of
comedications usage
- Random error

- Uncontrolled disease
severity
- Random error
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- Random error
- Recall bias
- Selection bias
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Table 3. (continued )
Data source

Study design

Herbal medicine

Conventional drug

Potential interactions/
Main ﬁndings

Potential methodological ﬂaws

Loquai et al. [17]

Questionnaire

Cross-sectional

Herbal medicines
(Mistletoe, Mushroom)

Melanoma treatments
(ipilimumab, interferon, etc.)

- Recall bias
- Survival bias
- Uncontrolled dose or
duration of herb
usage

Djuv et al. [18]

Questionnaire

Cross-sectional

Herbal medicines (Echinacea purpurea, Ginkgo
biloba, etc.)

Conventional drugs
(anti-infectives, anticoagulant, etc.)

McLay et al. [19]

Questionnaire

Cross-sectional

Herbal medicines
(Chamomile, Ginseng,
etc.)

Conventional drugs
(antibacterials, opiate
analgesics, etc.)

Mohammadi et al. [20]

Survey and electronic
health records

Cross-sectional

Herbal medicines
(Ginseng, Ginkgo, etc.)

Conventional drugs
(aspirin, clopidogrel,
etc.)

Levy et al. [21]

Survey and electronic
health records

Cross-sectional

Herbal medicines (Sage,
Chamomile, etc.)

Conventional drugs
(methadone, simvastatin, etc.)

Ting et al. [22]

Survey and electronic
health records

Cross-sectional

Herbal medicines (Aloe,
Ginseng, etc.)

Digoxin

Most patients (80%)
concomitantly received
a melanoma-speciﬁc
treatment and herbal
medicines, and some
of them were exposed
to potential herb-drug
interactions.
A high percentage of
herbal co-use was
observed among patients using conventional drugs in general
practice, especially in
elderly and chronically
ill patients.
Concurrent use of
herbal products and
prescription medicines
during pregnancy was
common and carried
potential risks.
The prevalence of
herbal supplement
usage among CKD patients was 18.6%. In the
study, ginseng had the
most possible interactions with prescription drugs.
One in 55 hospitalizations may have adverse
events associated with
herb-drug interactions,
which may worsen
existing medical
conditions.
Few patients took
herbal medicines that
could interact with
digoxin, and no clinically signiﬁcant herbdigoxin interactions
were observed.

- Random error
- Recall bias
- Selection bias

- Uncontrolled dose or
duration of herb
usage
- Recall bias
- Non-response bias
- Recall bias
- Selection bias
- Uncontrolled disease
severity

- Recall bias
- Selection bias
- Survival bias

- Random error
- Recall bias
- Selection bias
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Survey and electronic
health records

Cross-sectional

Herbal medicines (St.
John's wort,
Cannabis, etc.)

Antiretrovirals

Chi et al. [24]

Survey and electronic
health records

Cross-sectional

Herbal medicines
(Ginkgo, Licorice, etc.)

Conventional drugs
(anticoagulants, antiplatelets, etc.)

Levy et al. [25]

Survey and electronic
health records

Cross-sectional

Herbal medicines (Sage,
Chamomile, etc.)

Anesthetics and
antithrombotic drugs

Drozdoff et al. [26]

Survey and electronic
health records

Cohort

Herbal medicines (St
John's wort, Mistletoe,
etc.)

Gynecological cancer
therapy (taxane, antiHER2, etc.)

Traditional herbal
therapies were
commonly used by
HIV treatment naïve
outpatients of public
health facilities in
South Africa.
Among elderly participants who used any
herb and drug combinations, 43.3% were
exposed to at least one
potential herb-drug
interactions. Most of
them were related to
herbs with anticoagulant/antiplatelet
properties.
This study found that
44% patients used
herbal supplements.
Of these, 16.5% of the
herb usage could
potentially interact
with anesthesia and
10% of them could
potentially interact
with antithrombotic
drugs.
There was overall high
(74%) use of biologically based complementary and
alternative medication
in cancer patients undergoing systemic
therapy. However,
only 1 patient seemed
to be exposed to a potential clinically relevant herb-drug
interaction.

- Recall bias
- Selection bias

- Selection bias
- Survival bias

-

Recall bias
Selection bias
Survival bias
Uncontrolled dose or
duration of herb
usage

-

Random error
Recall bias
Selection bias
Uncontrolled dose or
duration of herb
usage
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Table 3. (continued )
Data source

Study design

Herbal medicine

Conventional drug

Potential interactions/
Main ﬁndings

Potential methodological ﬂaws

Jaradat et al. [27]

Survey and electronic
health records

Cross-sectional

Herbal medicines (Sage,
Anise, etc.)

Conventional drugs
(metformin, insulin,
etc.)

- Recall bias
- Selection bias
- Uncontrolled dose or
duration of herb
usage

Levy et al. [28]

Survey and electronic
health records

Cross-sectional

Herbal medicines
(Chamomile, Ginger,
etc.)

Conventional drugs
(antithrombotics,
quinolones, etc.)

Leung et al. [29]

Survey and electronic
health records

Cross-sectional

Complementary and
Alternative Medicine;
CAM (Ginkgo biloba,
Ginseng, etc.)

Warfarin

Use of medicinal herbs
was prevalent (59%)
among Palestinian patients attending primary healthcare
centers. Patients with
potential herb-drug
interactions were
older, having a higher
mean number of
chronic diseases and
medications.
Approximately half
patients took herbal
medicines during hospitalizations. Of them,
47% had at least one
potential herb-drug
interaction.
Around one-third of
patients used CAM
products with the potential to interact with
warfarin. The exposure
to CAM was not associated with an
increased risk of selfreported bleeding in
patients receiving
warfarin.

-Recall bias
-Selection bias
-Survival bias

- Random error
- Recall bias
- Confounding of
comedications usage
- Vaguely deﬁned
duration of herb
usage
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such as nested case-control study [33], casecrossover study [32], case-time control study [32],
and self-controlled case series [41], as well as new
user design coupled with an active-comparator
analysis [42], are currently all unused in herb-drug
interaction research. These designs and methods
can also be considered as potential means to mitigate bias and confounding. Overall, there is an
unmet need for understanding interactions between HM and conventional drug in present clinical settings primarily due to the limited evidence,
thus the implementation of newer or rigorous
methodologies may help bring herb-drug related
research to the next level. As the real-world evidence on the actual interactions between HMs and
conventional drugs are currently scarce, future
ﬁndings generated from these new approaches may
provide important insights on the combined use of
HMs with conventional drugs in terms of the
beneﬁcial or the harmful effect of herb-drug combinations in daily clinical practice.

6. Conclusions
Despite the limitations discussed in this review
paper, studies that utilized observational methodologies via different data sources and study designs
still reported informative ﬁndings regarding the
interactions between HM and conventional drug.
Depending on the types of real-world data used, the
aforementioned studies provided various information on the harmful and beneﬁcial effects of cousing HMs and conventional drugs, and the prevalence of potential herb-drug interactions. With the
lack of RCTs being conducted on herb-drug interactions primarily due to ethical considerations,
observational studies can step in and provide supporting evidence to complement future RCTs and
help to conﬁrm whether current herb-drug interaction ﬁndings reported in animal and in vitro
research can be translated to real-life settings. With
a continuous improvement in controlling and mitigating confounding and bias, well-regulated and
appropriately designed studies that utilize realworld data can serve as a useful tool in making
signiﬁcant contributions to improve the knowledge
about the clinical consequences of herb-drug consumption, and help healthcare professionals to
reinforce the herb-drug use where beneﬁts are
found and to prevent co-consumption where risks
are observed.
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